Recently, we have generated two ErbB3 monoclonal antibodies (MoAbs), namely A3 and A4, that negatively regulate the ErbB3-mediated signaling pathway, reducing the growth rate of cancer cells from different origins, either in vitro [7, 8] or in vivo [9]. Here, ERBB3 is linked to cancer.